Evidence and controversies on the role of XMRV in prostate cancer and chronic fatigue syndrome

Reviews in Medical Virology

Volumn 21, Issue 1, 2011, Pages 3-17

  Menéndez Arias, Luis ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3' AZIDO 2',3' DIDEOXYADENOSINE; 3' AZIDO 2',3' DIDEOXYGUANOSINE; ABACAVIR; ACICLOVIR; ANTIRETROVIRUS AGENT; APOLIPOPROTEIN B; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; BICALUTAMIDE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENTECAVIR; FLUTAMIDE; FOSCARNET; GAG PROTEIN; GANCICLOVIR; GLUCOCORTICOID; L 870812; LAMIVUDINE; NEVIRAPINE; PENCICLOVIR; PROTEIN APOBEC3; RALTEGRAVIR; RIBONUCLEASE L; STAVUDINE; TELBIVUDINE; TENOFOVIR; TETHERIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; BLOOD DONOR; BLOOD TRANSFUSION; CANCER CELL; CANCER DIAGNOSIS; CANCER INCIDENCE; CELL CULTURE; CHRONIC FATIGUE SYNDROME; DISEASE ASSOCIATION; DNA INTEGRATION; DNA MICROARRAY; DNA RESPONSIVE ELEMENT; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; POLYMERASE CHAIN REACTION; PREVALENCE; PROSTATE CANCER; RESTRICTION SITE; RETROVIRUS INFECTION; REVIEW; RISK FACTOR; TRANSCRIPTION INITIATION; VIRUS CARCINOGENESIS; VIRUS GENOME; VIRUS REPLICATION; VIRUS TRANSMISSION; WESTERN BLOTTING; XENOTRANSPLANTATION; XENOTROPIC MULV RELATED VIRUS; XENOTROPIC MULV RELATED VIRUS INFECTION;

ANIMALS; FATIGUE SYNDROME, CHRONIC; FEMALE; GENE EXPRESSION REGULATION, VIRAL; HUMANS; MALE; PROSTATIC NEOPLASMS; XENOTROPIC MURINE LEUKEMIA VIRUS-RELATED VIRUS;

EID: 79551625676     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.673     Document Type: Review

References (113)

1. Fan H. A new human retrovirus associated with prostate cancer. Proceedings of the National Academy of Sciences of the United States of America 2007; 104: 1449-1450.
2. Gjoerup O, Chang Y. Update on human polyomaviruses and cancer. Advances in Cancer Research 2010; 106: 1-51.
3. Tsai W-L, Chung RT. Viral hepatocarcinogenesis. Oncogene 2010; 29: 2309-2324.
4. Maeda N, Fan H, Yoshikai Y. Oncogenesis by retrovirus: old and new paradigms. Reviews in Medical Virology 2008; 18: 387-405.
5. Voisset C, Weiss RA, Griffiths DJ. Human RNA "rumor" viruses: the search for novel human retroviruses in chronic disease. Microbiology and Molecular Biology Reviews 2008; 72: 157-196.
6. Urisman A, Molinaro RJ, Fischer N, et al. Identification of a novel gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathogens 2006; 2: e25.
7. Lombardi VC, Ruscetti FW, Gupta JD, et al. Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science 2009; 326: 585-589.
8. Altekruse, SF, Kosary CL, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD, based on November 2009 SEER data submission, posted to the SEER web site, 2010.
9. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Annals of Oncology 2007; 18: 581-592.
10. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. The New England Journal of Medicine 2003; 349: 366-381.
11. Arnold RS, Makarova NV, Osunkoya AO, et al. XMRV infection in patients with prostate cancer: novel serologic assay and correlation with PCR and FISH. Urology 2010; 75: 755-761.
12. Schlaberg R, Choe DJ, Brown KR, Thaker HM, Singh IR. XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors. Proceedings of the National Academy of Sciences of the United States of America 2009; 106: 16351-16356.
13. Fischer N, Hellwinkel O, Schulz C, et al. Prevalence of human gammaretrovirus XMRV in sporadic prostate cancer. Journal of Clininical Virology 2008; 43: 277-283.
14. Hohn O, Krause H, Barbarotto P, et al. Lack of evidence for xenotropic murine leukemia virus-related virus (XMRV) in German prostate cancer patients. Retrovirology 2009; 6: 92.
15. Verhaegh GW, de Jong AS, Smit FP, Jannink SA, Melchers WJG, Schalken JA. Prevalence of human xenotropic murine leukemia virus-related gammaretrovirus (XMRV) in Dutch prostate cancer patients. The Prostate 2010; DOI: 10.1002/pros.21255.
16. D'Arcy F, Foley R, Perry A, et al. No evidence of XMRV in Irish prostate cancer patients with the R462Q mutation. European Urology Supplements 2008; 7: 271.
17. Martinez-Fierro ML, Leach RJ, Gomez-Guerra LS, et al. Identification of viral infections in the prostate and evaluation of their association with cancer. BMC Cancer 2010; 10: 326.
18. Sfanos KS, Sauvageot J, Fedor HL, Dick JD, De Marzo AM, Isaacs WB. A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms. The Prostate 2008; 68: 306-320.
19. Carpten J, Nupponen N, Isaacs S, et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nature Genetics 2002; 30: 181-184.
20. Casey G, Neville PJ, Plummer SJ, et al. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nature Genetics 2002; 32: 581-583.
21. Silverman RH. Implications for RNase L in prostate cancer biology. Biochemistry 2003; 42: 1805-1812.
22. Silverman RH. A scientific journey through the 2-5A/RNase L system. Cytokine & Growth Factor Reviews 2007; 18: 381-388.
23. Rennert H, Bercovich D, Hubert A, et al. A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews. American Journal of Human Genetics 2002; 71: 981-984.
24. Rökman A, Ikonen T, Seppälä EH, et al. Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. American Journal of Human Genetics 2002; 70: 1299-1304. Errata in: American Journal of Human Genetics 2002; 71: 215; American Journal of Human Genetics 2004; 75: 1158.
25. Maier C, Haeusler J, Herkommer K, et al. Mutation screening and association study of RNASEL as a prostate cancer susceptibility gene. British Journal of Cancer 2005; 92: 1159-1164.
26. Nakazato H, Suzuki K, Matsui H, Ohtake N, Nakata S, Yamanaka H. Role of genetic polymorphisms of the RNASEL gene on familial prostate cancer risk in a Japanese population. British Journal of Cancer 2003; 89: 691-696.
27. Bartsch DK, Fendrich V, Slater EP, et al. RNASEL germline variants are associated with pancreatic cancer. International Journal of Cancer 2005; 117: 718-722.
28. Malathi K, Paranjape JM, Bulanova E, et al. A transcriptional signaling pathway in the IFN system mediated by 2'-5'-oligoadenylate activation of RNase L. Proceedings of the National Academy of Sciences of the United States of America 2005; 102: 14533-14538.
29. Dong B, Kim S, Hong S, et al. An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors. Proceedings of the National Academy of Sciences of the United States of America 2007; 104: 1655-1660.
30. Wang L, McDonnell SK, Elkins DA, et al. Analysis of the RNASEL gene in familial and sporadic prostate cancer. American Journal of Human Genetics 2002; 71: 116-123.
31. Downing SR, Hennessy KT, Abe M, Manola J, George DJ, Kantoff PW. Mutations in ribonuclease L gene do not occur at a greater frequency in patients with familial prostate cancer compared with patients with sporadic prostate cancer. Clinical Prostate Cancer 2003; 2: 177-180.
32. Wiklund F, Jonsson BA, Brookes AJ, et al. Genetic analysis of the RNASEL gene in hereditary, familial, and sporadic prostate cancer. Clinical Cancer Research 2004; 10: 7150-7156.
33. Li H, Tai BC. RNASEL gene polymorphisms and the risk of prostate cancer: a meta-analysis. Clinical Cancer Research 2006; 12: 5713-5719.
34. Devanur LD, Kerr JR. Chronic fatigue syndrome. Journal of Clinical Virology 2006; 37: 139-150.
35. Prins JB, van der Meer JW, Bleijenberg G. Chronic fatigue syndrome. Lancet 2006; 367: 346-355.
36. Silverman RH, Nguyen C, Weight CJ, Klein EA. The human retrovirus XMRV in prostate cancer and chronic fatigue syndrome. Nature Reviews Urology 2010; 7: 392-402.
37. Erlwein O, Kaye S, McClure MO, et al. Failure to detect the novel retrovirus XMRV in chronic fatigue syndrome. PLoS ONE 2010; 5: e8519.
38. Groom HCT, Boucherit VC, Makinson K, et al. Absence of xenotropic murine leukaemia virus-related virus in UK patients with chronic fatigue syndrome. Retrovirology 2010; 7: 10.
39. van Kuppeveld FJM, de Jong AS, Lanke KH, et al. Prevalence of xenotropic murine leukaemia virus-related virus in patients with chronic fatigue syndrome in the Netherlands: retrospective analysis of samples from an established cohort. British Medical Journal 2010; 340: c1018.
40. Hong P, Li J, Li Y. Failure to detect xenotropic murine leukaemia virus-related virus in Chinese patients with chronic fatigue syndrome. Virology Journal 2010; 7: 224.
41. Switzer WM, Jia H, Hohn O, et al. Absence of evidence of xenotropic murine leukemia virus-related virus infection in persons with chronic fatigue syndrome and healthy controls in the United States. Retrovirology 2010; 7: 57.
42. Sudlow C, Macleod M, Salman RA, Stone J. Comment on "detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome". Science 2010; 328: 825-a.
43. Lloyd A, White P, Wessely S, Sharpe M, Buchwald D. Comment on "detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome". Science 2010; 328: 825-b.
44. van der Meer JWM, Netea MG, Galama JMD, van Kuppeveld FJM. Comment on "detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome". Science 2010; 328: 825-c.
45. Lo S-C, Pripuzova N, Li B, et al. Detection of MLV-related virus gene sequences in blood of patients with chronic fatigue syndrome and healthy blood donors. Proceedings of the National Academy of Sciences of the United States of America 2010; 107: 15874-15879.
46. DeFreitas E, Hilliard B, Cheney PR, et al. Retroviral sequences related to human T-lymphotropic virus type II in patients with chronic fatigue immune dysfunction syndrome. Proceedings of the National Academy of Sciences of the United States of America 1991; 88: 2922-2926.
47. Raisch KP, Pizzato M, Sun H-Y, Takeuchi Y, Cashdollar LW, Grossberg SE. Molecular cloning, complete sequence, and biological characterization of a xenotropic murine leukemia virus constitutively released from the human B-lymphoblastoid cell line DG-75. Virology 2003; 308: 83-91.
48. Stoye JP, Coffin JM. The four classes of endogenous murine leukemia virus: structural relationships and potential for recombination. Journal of Virology 1987; 61: 2659-2669.
49. Feng Y-X, Copeland TD, Oroszlan S, Rein A, Levin JG. Identification of amino acids inserted during suppression of UAA and UGA termination codons at the gag-pol junction of Moloney murine leukemia virus. Proceedings of the National Academy of Sciences of the United States of America 1990; 87: 8860-8863.
50. Levy JA. Xenotropism: the elusive viral receptor finally uncovered. Proceedings of the National Academy of Sciences of the United States of America 1999; 96: 802-804.
51. Coffin JM, Stoye JP. A new virus for old diseases? Science 2009; 326: 530-531.
52. Battini J-L, Rasko JEJ, Miller AD. A human cell-surface receptor for xenotropic and polytropic murine leukemia viruses: possible role in G protein-coupled signal transduction. Proceedings of the National Academy of Sciences of the United States of America 1999; 96: 1385-1390.
53. Tailor CS, Nouri A, Lee CG, Kozak C, Kabat D. Cloning and characterization of a cell surface receptor for xenotropic and polytropic murine leukemia viruses. Proceedings of the National Academy of Sciences of the United States of America 1999; 96: 927-932.
54. Yang Y-L, Guo L, Xu S, et al. Receptors for polytropic and xenotropic mouse leukaemia viruses encoded by a single gene at Rmc1. Nature Genetics 1999; 21: 216-219.
55. Marin M, Tailor CS, Nouri A, Kozak SL, Kabat D. Polymorphisms of the cell surface receptor control mouse susceptibilities to xenotropic and polytropic leukemia viruses. Journal of Virology 1999; 73: 9362-9368.
56. Van Hoeven NS, Miller AD. Use of different but overlapping determinants in a retrovirus receptor accounts for non-reciprocal interference between xenotropic and polytropic murine leukemia viruses. Retrovirology 2005; 2: 76.
57. Bhosle S, Suppiah S, Molinaro R, et al. Evaluation of cellular determinants required for in vitro xenotropic murine leukemia virus-related virus entry into human prostate cancer and noncancerous cells. Journal of Virology 2010; 84: 6288-6296.
58. Yan Y, Knoper RC, Kozak CA. Wild mouse variants of envelope genes of xenotropic/polytropic mouse gammaretroviruses and their XPR1 receptors elucidate receptor determinants of virus entry. Journal of Virology 2007; 81: 10550-10557.
59. Yan Y, Liu Q, Kozak CA. Six host range variants of the xenotropic/polytropic gammaretroviruses define determinants for entry in the XPR1 cell surface receptor. Retrovirology 2009; 6: 87.
60. Yan Y, Liu Q, Wollenberg K, Martin C, Buckler-White A, Kozak CA. Evolution of functional and sequence variants of the mammalian XPR1 receptor for mouse xenotropic gammaretroviruses and the human-derived XMRV. Journal of Virology 2010; 84: 11970-11980.
61. Münch J, Rücker E, Ständker L, et al. Semen-derived amyloid fibrils drastically enhance HIV infection. Cell 2007; 131: 1059-1071.
62. Hong S, Klein EA, Gupta JD, et al. Fibrils of prostatic acid phosphatase fragments boost infections with XMRV (xenotropic murine leukemia virus-related virus), a human retrovirus associated with prostate cancer. Journal of Virology 2009; 83: 6995-7003.
63. Brass AL, Dykxhoorn DM, Benita Y, et al. Identification of host proteins required for HIV infection through a functional genomic screen. Science 2008; 319: 921-926.
64. König R, Zhou Y, Elleder D, et al. Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell 2008; 135: 49-60.
65. Zhou H, Xu M, Huang Q, et al. Genome-scale RNAi screen for host factors required for HIV replication. Cell Host Microbe 2008; 4: 495-504.
66. Strebel K, Luban J, Jeang K-T. Human cellular restriction factors that target HIV-1 replication. BMC Medicine 2009; 7: 48.
67. Doehle BP, Schäfer A, Wiegand HL, Bogerd HP, Cullen BR. Differential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion. Journal of Virology 2005; 79: 8201-8207.
68. Rulli SJ Jr, Mirro J, Hill SA, et al. Interactions of murine APOBEC3 and human APOBEC3G with murine leukemia viruses. Journal of Virology 2008; 82: 6566-6575.
69. Yap MW, Nisole S, Lynch C, Stoye JP. TRIM5α protein restricts both HIV-1 and murine leukemia virus. Proceedings of the National Academy of Sciences of the United States of America 2004; 101: 10786-10791.
70. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008; 451: 425-430.
71. Jouvenet N, Neil SJ, Zhadina M, et al. Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. Journal of Virology 2009; 83: 1837-1844.
72. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002; 418: 646-650.
73. Langlois M-A, Kemmerich K, Rada C, Neuberger MS. The AKV murine leukemia virus is restricted and hypermutated by mouse APOBEC3. Journal of Virology 2009; 83: 11550-11559.
74. Sanville B, Dolan MA, Wollenberg K, et al. Adaptive evolution of Mus Apobec3 includes retroviral insertion and positive selection of two clusters of residues flanking the substrate groove. PLoS Pathogens 2010; 6: e1000974.
75. Groom HCT, Yap MW, Galão RP, Neil SJD, Bishop KN. Susceptibility of xenotropic murine leukemia virus-related virus (XMRV) to retroviral restriction factors. Proceedings of the National Academy of Sciences of the United States of America 2010; 107: 5166-5171.
76. Paprotka T, Venkatachari NJ, Chaipan C, et al. Inhibition of xenotropic murine leukemia virus-related virus by APOBEC3 proteins and antiviral drugs. Journal of Virology 2010; 84: 5719-5729.
77. Stieler K, Fischer N. Apobec 3G efficiently reduces infectivity of the human exogenous gammaretrovirus XMRV. PLoS ONE 2010; 5: e11738.
78. Stopak KS, Chiu Y-L, Kropp J, Grant RM, Greene WC. Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells. The Journal of Biology Chemistry 2007; 282: 3539-3546.
79. Koning FA, Newman ENC, Kim E-Y, Kunstman KJ, Wolinsky SM, Malim MH. Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. Journal of Virology 2009; 83: 9474-9485.
80. Metzger MJ, Holguin C, Mendoza R, Miller AD. The prostate cancer-associated human retrovirus XMRV lacks direct transforming activity but can induce low rates of transformation in cultured cells. Journal of Virology 2010; 84: 1874-1880.
81. Lassaux A, Sitbon M, Battini JL. Residues in the murine leukemia capsid that differentially govern resistance to mouse Fv1 and human Ref1 restrictions. Journal of Virology 2005; 79: 6560-6564.
82. Knouf EC, Metzger MJ, Mitchell PS, et al. Multiple integrated copies and high-level production of the human retrovirus XMRV (xenotropic murine leukemia virus-related virus) from 22Rv1 prostate carcinoma cells. Journal of Virology 2009; 83: 7353-7356.
83. Kim S, Kim N, Dong B, et al. Integration site preference of xenotropic murine leukemia virus-related virus, a new human retrovirus associated with prostate cancer. Journal of Virology 2008; 82: 9964-9977.
84. Desfarges S, Ciuffi A. Retroviral integration site selection. Viruses 2010; 2: 111-130.
85. Kim S, Rusmevichientong A, Dong B, Remenyi R, Silverman RH, Chow SA. Fidelity of target site duplication and sequence preference during integration of xenotropic murine leukemia virus-related virus. PLoS ONE 2010; 5: e10255.
86. Memarzadeh S, Xin L, Mulholland DJ, et al. Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell 2007; 12: 572-585.
87. Dong B, Silverman RH. Androgen stimulates transcription and replication of xenotropic murine leukemia virus-related virus. Journal of Virology 2010; 84: 1648-1651.
88. Rodriguez JJ, Goff SP. Xenotropic murine leukemia virus-related virus establishes an efficient spreading infection and exhibits enhanced transcriptional activity in prostate carcinoma cells. Journal of Virology 2010; 84: 2556-2562.
89. Mani RS, Tomlins SA, Callahan K, et al. Induced chromosomal proximity and gene fusions in prostate cancer. Science 2009; 326: 1230.
90. Menéndez-Arias L. Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase. Virus Research 2008; 134: 124-146.
91. Menéndez-Arias L. Molecular basis of human immunodeficiency virus drug resistance: an update. Antiviral Research 2010; 85: 210-231.
92. Sakuma R, Sakuma T, Ohmine S, Silverman RH, Ikeda Y. Xenotropic murine leukemia virus-related virus is susceptible to AZT. Virology 2010; 397: 1-6.
93. Singh IR, Gorzynski JE, Drobysheva D, Bassit L, Schinazi RF. Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome. PLoS ONE 2010; 5: e9948.
94. Smith SA, Gottlieb GS, Miller AD. Susceptibility of the human retrovirus XMRV to antiretroviral inhibitors. Retrovirology 2010; 7: 70.
95. Menéndez-Arias L, Weber IT, Soss J, Harrison RW, Gotte D, Oroszlan S. Kinetic and modeling studies of subsites S4-S3' of Moloney murine leukemia virus protease. The Journal of Biological Chemistry 1994; 269: 16795-16801.
96. Menéndez-Arias L, Weber IT, Oroszlan S. Mutational analysis of the substrate binding pocket of murine leukemia virus protease and comparison with human immunodeficiency virus proteases. The Journal of Biological Chemistry 1995; 270: 29162-29168.
97. Menéndez-Arias L, Gotte D, Oroszlan S. Moloney murine leukemia virus protease: bacterial expression and characterization of the purified enzyme. Virology 1993; 196: 557-563.
98. Álvarez E, Menéndez-Arias L, Carrasco L. The eukaryotic translation initiation factor 4GI is cleaved by different retroviral proteases. Journal of Virology 2003; 77: 12392-12400.
99. Li M, DiMaio F, Zhou D, et al. Crystal structure of XMRV protease significantly differs from the structures of other retropepsins. Nature Structural and Molecular Biology 2010; in press
100. Nair V, Chi G. HIV inhibitors as therapeutic agents in AIDS. Reviews in Medical Virology 2007; 17: 277-295.
101. Hicks C, Gulick RM. Raltegravir: the first HIV type 1 integrase inhibitor. Clinical Infectious Diseases 2009; 48: 931-939.
102. Sato M, Motomura T, Aramaki H, et al. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. Journal of Medicinal Chemistry 2006; 49: 1506-1508.
103. Hazuda DJ, Young SD, Guare JP, et al. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 2004; 305: 528-532.
104. Pfeifer A, Verma IM. Gene therapy: promises and problems. Annual Review of Genomics and Human Genetics 2001; 2: 177-211.
105. Tai CK, Kasahara N. Replication-competent retrovirus vectors for cancer gene therapy. Frontiers in Bioscience 2008; 13: 3083-3095.
106. Denner J. Transspecies transmissions of retroviruses: new cases. Virology 2007; 369: 229-233.
107. Denner J. Detection of a gammaretrovirus, XMRV, in the human population: open questions and implications for xenotransplantation. Retrovirology 2010; 7: 16.
108. Tarlinton RE, Meers J, Young PR. Retroviral invasion of the koala genome. Nature 2006; 442: 79-81.
109. Wilson CA. Porcine endogenous retroviruses and xenotransplantation. Cellular and Molecular Life Sciences 2008; 65: 3399-3412.
110. Louz D, Bergmans HE, Loos BP, Hoeben RC. Reappraisal of biosafety risks posed by PERVs in xenotransplantation. Reviews in Medical Virology 2008; 18: 53-65.
111. Suling K, Quinn G, Wood J, Patience C. Packaging of human endogenous retrovirus sequences is undetectable in porcine endogenous retrovirus particles produced from human cells. Virology 2003; 312: 330-336.
112. Martina Y, Kurian S, Cherqui S, Evanoff G, Wilson C, Salomon DR. Pseudotyping of porcine endogenous retrovirus by xenotropic murine leukemia virus in a pig islet xenotransplantation model. American Journal of Transplantation 2005; 5: 1837-1847.
113. Enserink M. Conflicting papers on hold as XMRV frenzy reaches new heights. Science 2010; 329: 18-19.